Q4 2025 Ligand Pharmaceuticals Inc Earnings Call Transcript

Feb 26, 2026 / 01:30 PM GMT

Release Date Price: €166 (+2.47%)

Transcript 10-K8-K

Key Points

Positve

Ligand Pharmaceuticals Inc (LGND) exceeded its original 2025 guidance with full-year adjusted EPS surpassing expectations by more than 30%.
Royalty revenue grew by 48% year-over-year, driven by successful product launches and strong portfolio performance.
The company has substantial cash and investments, positioning it well for disciplined investments to enhance long-term shareholder value.
Positive Phase 3 trial results for ketorin rapamycin, potentially the first FDA-approved therapy for microcystic lymphatic malformations, were announced.
Ligand Pharmaceuticals Inc (LGND) has a strong pipeline with a 23% compound annual growth rate expected in royalty receipts from 2025 through 2030.

Negative

The FDA extended the review timeline for Filspari in FSGS, potentially impacting the timing of revenue from this indication.
The company's 2026 adjusted EPS growth appears modest due to a one-time out-licensing income recognized in 2025.
There is a relatively modest assumption for FSGS royalties in the 2026 guidance, indicating potential uncertainty in this area.
R&D expenses increased significantly in 2025 due to accounting treatments related to specific investments.
The market for royalty financing is competitive, requiring Ligand Pharmaceuticals Inc (LGND) to aggressively manage its pipeline of opportunities.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LGND.OQ - Ligand Pharmaceuticals Inc
Q4 2025 Ligand Pharmaceuticals Inc Earnings Call
Feb 26, 2026 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for standing by and welcome to Lin 4th quarter 2025 earnings call. All lines have been placed on mute to a pen and a background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, seem to press the star, followed by the number 1 on your telephone keypad. If you would like to withdraw your question, please press the store 1 again.

Thank you. I would now like to turn the conference over to Melanie Herman, who may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.